So-called subclinical hypothyroidism is characterised by an elevated blood level of the pituitary hormone TSH but with a normal blood concentration of the thyroid hormone free T4.
Symptoms reported in subclinical hypothyroidism are rare and are not very specific. The progression to proven hypothyroidism is slow and inconsistent.
As of early 2020, there is no strong evidence of a benefit of thyroid hormone treatment, most commonly levothyroxine, in reducing mortality or the frequency of cardiovascular complications in adults with subclinical hypothyroidism.
In 2018, a systematic review of clinical trials (approximately 2 000 patients in total) evaluated the effect of this treatment on patients’ self-reported symptoms and quality of life.
This review showed no perceptible effect for patients on the following criteria: symptoms considered to be related to hypothyroidism, fatigue, depressive symptoms, cognitive function. Likewise for the quality of life evaluated by different scores and body mass index after 12 months of thyroid hormone treatment. This supports the option of not routinely offering thyroid hormone treatment to patients with asymptomatic, incidentally discovered subclinical hypothyroidism.
©Prescrire 1 June 2020
Source: "Subclinical hypothyroidism. No proof of benefit from treatment with thyroid hormone" Prescrire International 2020; 29 (216): 160. Subscribers only.
Enjoy full access to Prescrire International, and support independent information
|